Loading…

Measurement of complexed PSA improves specificity for early detection of prostate cancer

Objectives. Prostate-specific antigen (PSA) is the most useful of all tumor markers. Although the sensitivity is impressive, low specificity results in a lack of cancer detection in a significant proportion of patients undergoing prostate biopsy. Several recent studies have addressed the need for im...

Full description

Saved in:
Bibliographic Details
Published in:Urology (Ridgewood, N.J.) N.J.), 1998-09, Vol.52 (3), p.372-378
Main Authors: Brawer, Michael K., Meyer, Grant E., Letran, Jason L., Bankson, Dan D., Morris, Deborah L., Yeung, Kwok K., Allard, W.Jeffrey
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c418t-5a09a330ff4d36d4e929e76f36952b10b3e9fc23b2f0576ce1e92a2e0aab39023
cites cdi_FETCH-LOGICAL-c418t-5a09a330ff4d36d4e929e76f36952b10b3e9fc23b2f0576ce1e92a2e0aab39023
container_end_page 378
container_issue 3
container_start_page 372
container_title Urology (Ridgewood, N.J.)
container_volume 52
creator Brawer, Michael K.
Meyer, Grant E.
Letran, Jason L.
Bankson, Dan D.
Morris, Deborah L.
Yeung, Kwok K.
Allard, W.Jeffrey
description Objectives. Prostate-specific antigen (PSA) is the most useful of all tumor markers. Although the sensitivity is impressive, low specificity results in a lack of cancer detection in a significant proportion of patients undergoing prostate biopsy. Several recent studies have addressed the need for improved specificity. Of all these approaches, the free/total PSA ratio appears to be the most promising. Given that most circulating PSA is complexed to alpha 1-antichymotrypsin, and that this moiety represents a greater proportion of the total PSA in those men with carcinoma, we set out to determine whether complexed PSA would improve specificity in the detection of men with prostate cancer. Methods. Archival sera were obtained from 300 men, 75 of whom had biopsy-proved prostate cancer. All sera had been previously stored at −70°C for variable periods. An investigative assay for complexed PSA (Bayer) was used. The Tandem-R free and total PSA assays (Hybritech) were used according to the manufacturer’s recommendations. Results. Among all patients, specificities for the total PSA, free/total PSA, and complexed PSA alone were 21.8%, 15.6%, and 26.7%, respectively, at cutoffs yielding 95% sensitivity. Similar equivalence or superior performance, in terms of specificity relative to the free/total PSA ratio, was seen at other sensitivity thresholds and other total PSA ranges. Conclusions. Complexed PSA alone performs better than total PSA or the free/total PSA ratio and obviates the need for a second analyte determination. We believe this marker may offer significant enhancement in PSA testing with significant economic advantages.
doi_str_mv 10.1016/S0090-4295(98)00241-6
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73889951</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090429598002416</els_id><sourcerecordid>73889951</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-5a09a330ff4d36d4e929e76f36952b10b3e9fc23b2f0576ce1e92a2e0aab39023</originalsourceid><addsrcrecordid>eNqFkMtKAzEUhoMoWi-PIGQhoovRk2QmM1lJEW-gKFTBXchkTiAy06nJtNi3N7WlW1dncb7_XD5CThlcMWDyegKgIMu5Ki5UdQnAc5bJHTJiBS8zpVSxS0Zb5IAcxvgFAFLKcp_sq1JAnssR-XxBE-cBO5wOtHfU9t2sxR9s6NtkTH03C_0CI40ztN5564cldX2gaEK7pA0OaAffT1fJRMbBDEitmVoMx2TPmTbiyaYekY_7u_fbx-z59eHpdvyc2ZxVQ1YYUEYIcC5vhGxyVFxhKZ2QquA1g1qgcpaLmjsoSmmRJcJwBGNqoYCLI3K-npv2f88xDrrz0WLbmin286hLUVVJBktgsQZtOjQGdHoWfGfCUjPQK6P6z6he6dKq0n9GtUy5082Ced1hs01tFKb-2aZvojWtC-l9H7cYF1UpyjxhN2sMk4yFx6Cj9ZhMNT4kibrp_T-H_ALX55Ly</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73889951</pqid></control><display><type>article</type><title>Measurement of complexed PSA improves specificity for early detection of prostate cancer</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Brawer, Michael K. ; Meyer, Grant E. ; Letran, Jason L. ; Bankson, Dan D. ; Morris, Deborah L. ; Yeung, Kwok K. ; Allard, W.Jeffrey</creator><creatorcontrib>Brawer, Michael K. ; Meyer, Grant E. ; Letran, Jason L. ; Bankson, Dan D. ; Morris, Deborah L. ; Yeung, Kwok K. ; Allard, W.Jeffrey</creatorcontrib><description>Objectives. Prostate-specific antigen (PSA) is the most useful of all tumor markers. Although the sensitivity is impressive, low specificity results in a lack of cancer detection in a significant proportion of patients undergoing prostate biopsy. Several recent studies have addressed the need for improved specificity. Of all these approaches, the free/total PSA ratio appears to be the most promising. Given that most circulating PSA is complexed to alpha 1-antichymotrypsin, and that this moiety represents a greater proportion of the total PSA in those men with carcinoma, we set out to determine whether complexed PSA would improve specificity in the detection of men with prostate cancer. Methods. Archival sera were obtained from 300 men, 75 of whom had biopsy-proved prostate cancer. All sera had been previously stored at −70°C for variable periods. An investigative assay for complexed PSA (Bayer) was used. The Tandem-R free and total PSA assays (Hybritech) were used according to the manufacturer’s recommendations. Results. Among all patients, specificities for the total PSA, free/total PSA, and complexed PSA alone were 21.8%, 15.6%, and 26.7%, respectively, at cutoffs yielding 95% sensitivity. Similar equivalence or superior performance, in terms of specificity relative to the free/total PSA ratio, was seen at other sensitivity thresholds and other total PSA ranges. Conclusions. Complexed PSA alone performs better than total PSA or the free/total PSA ratio and obviates the need for a second analyte determination. We believe this marker may offer significant enhancement in PSA testing with significant economic advantages.</description><identifier>ISSN: 0090-4295</identifier><identifier>EISSN: 1527-9995</identifier><identifier>DOI: 10.1016/S0090-4295(98)00241-6</identifier><identifier>PMID: 9730446</identifier><identifier>CODEN: URGYAZ</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Aged, 80 and over ; Biological and medical sciences ; Humans ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnosis ; Retrospective Studies ; Sensitivity and Specificity ; Time Factors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>Urology (Ridgewood, N.J.), 1998-09, Vol.52 (3), p.372-378</ispartof><rights>1998 Elsevier Science Inc.</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-5a09a330ff4d36d4e929e76f36952b10b3e9fc23b2f0576ce1e92a2e0aab39023</citedby><cites>FETCH-LOGICAL-c418t-5a09a330ff4d36d4e929e76f36952b10b3e9fc23b2f0576ce1e92a2e0aab39023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2387374$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9730446$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brawer, Michael K.</creatorcontrib><creatorcontrib>Meyer, Grant E.</creatorcontrib><creatorcontrib>Letran, Jason L.</creatorcontrib><creatorcontrib>Bankson, Dan D.</creatorcontrib><creatorcontrib>Morris, Deborah L.</creatorcontrib><creatorcontrib>Yeung, Kwok K.</creatorcontrib><creatorcontrib>Allard, W.Jeffrey</creatorcontrib><title>Measurement of complexed PSA improves specificity for early detection of prostate cancer</title><title>Urology (Ridgewood, N.J.)</title><addtitle>Urology</addtitle><description>Objectives. Prostate-specific antigen (PSA) is the most useful of all tumor markers. Although the sensitivity is impressive, low specificity results in a lack of cancer detection in a significant proportion of patients undergoing prostate biopsy. Several recent studies have addressed the need for improved specificity. Of all these approaches, the free/total PSA ratio appears to be the most promising. Given that most circulating PSA is complexed to alpha 1-antichymotrypsin, and that this moiety represents a greater proportion of the total PSA in those men with carcinoma, we set out to determine whether complexed PSA would improve specificity in the detection of men with prostate cancer. Methods. Archival sera were obtained from 300 men, 75 of whom had biopsy-proved prostate cancer. All sera had been previously stored at −70°C for variable periods. An investigative assay for complexed PSA (Bayer) was used. The Tandem-R free and total PSA assays (Hybritech) were used according to the manufacturer’s recommendations. Results. Among all patients, specificities for the total PSA, free/total PSA, and complexed PSA alone were 21.8%, 15.6%, and 26.7%, respectively, at cutoffs yielding 95% sensitivity. Similar equivalence or superior performance, in terms of specificity relative to the free/total PSA ratio, was seen at other sensitivity thresholds and other total PSA ranges. Conclusions. Complexed PSA alone performs better than total PSA or the free/total PSA ratio and obviates the need for a second analyte determination. We believe this marker may offer significant enhancement in PSA testing with significant economic advantages.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Retrospective Studies</subject><subject>Sensitivity and Specificity</subject><subject>Time Factors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0090-4295</issn><issn>1527-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNqFkMtKAzEUhoMoWi-PIGQhoovRk2QmM1lJEW-gKFTBXchkTiAy06nJtNi3N7WlW1dncb7_XD5CThlcMWDyegKgIMu5Ki5UdQnAc5bJHTJiBS8zpVSxS0Zb5IAcxvgFAFLKcp_sq1JAnssR-XxBE-cBO5wOtHfU9t2sxR9s6NtkTH03C_0CI40ztN5564cldX2gaEK7pA0OaAffT1fJRMbBDEitmVoMx2TPmTbiyaYekY_7u_fbx-z59eHpdvyc2ZxVQ1YYUEYIcC5vhGxyVFxhKZ2QquA1g1qgcpaLmjsoSmmRJcJwBGNqoYCLI3K-npv2f88xDrrz0WLbmin286hLUVVJBktgsQZtOjQGdHoWfGfCUjPQK6P6z6he6dKq0n9GtUy5082Ced1hs01tFKb-2aZvojWtC-l9H7cYF1UpyjxhN2sMk4yFx6Cj9ZhMNT4kibrp_T-H_ALX55Ly</recordid><startdate>19980901</startdate><enddate>19980901</enddate><creator>Brawer, Michael K.</creator><creator>Meyer, Grant E.</creator><creator>Letran, Jason L.</creator><creator>Bankson, Dan D.</creator><creator>Morris, Deborah L.</creator><creator>Yeung, Kwok K.</creator><creator>Allard, W.Jeffrey</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980901</creationdate><title>Measurement of complexed PSA improves specificity for early detection of prostate cancer</title><author>Brawer, Michael K. ; Meyer, Grant E. ; Letran, Jason L. ; Bankson, Dan D. ; Morris, Deborah L. ; Yeung, Kwok K. ; Allard, W.Jeffrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-5a09a330ff4d36d4e929e76f36952b10b3e9fc23b2f0576ce1e92a2e0aab39023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Retrospective Studies</topic><topic>Sensitivity and Specificity</topic><topic>Time Factors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brawer, Michael K.</creatorcontrib><creatorcontrib>Meyer, Grant E.</creatorcontrib><creatorcontrib>Letran, Jason L.</creatorcontrib><creatorcontrib>Bankson, Dan D.</creatorcontrib><creatorcontrib>Morris, Deborah L.</creatorcontrib><creatorcontrib>Yeung, Kwok K.</creatorcontrib><creatorcontrib>Allard, W.Jeffrey</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urology (Ridgewood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brawer, Michael K.</au><au>Meyer, Grant E.</au><au>Letran, Jason L.</au><au>Bankson, Dan D.</au><au>Morris, Deborah L.</au><au>Yeung, Kwok K.</au><au>Allard, W.Jeffrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Measurement of complexed PSA improves specificity for early detection of prostate cancer</atitle><jtitle>Urology (Ridgewood, N.J.)</jtitle><addtitle>Urology</addtitle><date>1998-09-01</date><risdate>1998</risdate><volume>52</volume><issue>3</issue><spage>372</spage><epage>378</epage><pages>372-378</pages><issn>0090-4295</issn><eissn>1527-9995</eissn><coden>URGYAZ</coden><abstract>Objectives. Prostate-specific antigen (PSA) is the most useful of all tumor markers. Although the sensitivity is impressive, low specificity results in a lack of cancer detection in a significant proportion of patients undergoing prostate biopsy. Several recent studies have addressed the need for improved specificity. Of all these approaches, the free/total PSA ratio appears to be the most promising. Given that most circulating PSA is complexed to alpha 1-antichymotrypsin, and that this moiety represents a greater proportion of the total PSA in those men with carcinoma, we set out to determine whether complexed PSA would improve specificity in the detection of men with prostate cancer. Methods. Archival sera were obtained from 300 men, 75 of whom had biopsy-proved prostate cancer. All sera had been previously stored at −70°C for variable periods. An investigative assay for complexed PSA (Bayer) was used. The Tandem-R free and total PSA assays (Hybritech) were used according to the manufacturer’s recommendations. Results. Among all patients, specificities for the total PSA, free/total PSA, and complexed PSA alone were 21.8%, 15.6%, and 26.7%, respectively, at cutoffs yielding 95% sensitivity. Similar equivalence or superior performance, in terms of specificity relative to the free/total PSA ratio, was seen at other sensitivity thresholds and other total PSA ranges. Conclusions. Complexed PSA alone performs better than total PSA or the free/total PSA ratio and obviates the need for a second analyte determination. We believe this marker may offer significant enhancement in PSA testing with significant economic advantages.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9730446</pmid><doi>10.1016/S0090-4295(98)00241-6</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-4295
ispartof Urology (Ridgewood, N.J.), 1998-09, Vol.52 (3), p.372-378
issn 0090-4295
1527-9995
language eng
recordid cdi_proquest_miscellaneous_73889951
source Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)
subjects Aged
Aged, 80 and over
Biological and medical sciences
Humans
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood
Prostatic Neoplasms - diagnosis
Retrospective Studies
Sensitivity and Specificity
Time Factors
Tumors of the urinary system
Urinary tract. Prostate gland
title Measurement of complexed PSA improves specificity for early detection of prostate cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-09T03%3A46%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Measurement%20of%20complexed%20PSA%20improves%20specificity%20for%20early%20detection%20of%20prostate%20cancer&rft.jtitle=Urology%20(Ridgewood,%20N.J.)&rft.au=Brawer,%20Michael%20K.&rft.date=1998-09-01&rft.volume=52&rft.issue=3&rft.spage=372&rft.epage=378&rft.pages=372-378&rft.issn=0090-4295&rft.eissn=1527-9995&rft.coden=URGYAZ&rft_id=info:doi/10.1016/S0090-4295(98)00241-6&rft_dat=%3Cproquest_cross%3E73889951%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c418t-5a09a330ff4d36d4e929e76f36952b10b3e9fc23b2f0576ce1e92a2e0aab39023%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73889951&rft_id=info:pmid/9730446&rfr_iscdi=true